ProPhase Labs Statistics
Total Valuation
ProPhase Labs has a market cap or net worth of $93.11 million. The enterprise value is $109.22 million.
| Market Cap | 93.11M |
| Enterprise Value | 109.22M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ProPhase Labs has 18.05 million shares outstanding. The number of shares has decreased by -7.74% in one year.
| Shares Outstanding | 18.05M |
| Shares Change (YoY) | -7.74% |
| Shares Change (QoQ) | +5.13% |
| Owned by Insiders (%) | 22.06% |
| Owned by Institutions (%) | 9.54% |
| Float | 14.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.10 |
| Forward PS | 4.15 |
| PB Ratio | 1.89 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.43.
| Current Ratio | 2.28 |
| Quick Ratio | 1.99 |
| Debt / Equity | 0.43 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.88 |
Financial Efficiency
Return on equity (ROE) is -29.80% and return on invested capital (ROIC) is -30.54%.
| Return on Equity (ROE) | -29.80% |
| Return on Assets (ROA) | -18.10% |
| Return on Capital (ROIC) | -30.54% |
| Revenue Per Employee | $392,779 |
| Profits Per Employee | -$148,513 |
| Employee Count | 113 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 7.20 |
Taxes
| Income Tax | -6.02M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.10% in the last 52 weeks. The beta is -0.27, so ProPhase Labs's price volatility has been lower than the market average.
| Beta (1Y) | -0.27 |
| 52-Week Price Change | -34.10% |
| 50-Day Moving Average | 5.51 |
| 200-Day Moving Average | 5.21 |
| Relative Strength Index (RSI) | 42.02 |
| Average Volume (30 Days) | 51,293 |
Short Selling Information
The latest short interest is 257,323, so 1.43% of the outstanding shares have been sold short.
| Short Interest | 257,323 |
| Short Previous Month | 248,186 |
| Short % of Shares Out | 1.43% |
| Short % of Float | 1.83% |
| Short Ratio (days to cover) | 7.89 |
Income Statement
In the last 12 months, ProPhase Labs had revenue of $44.38 million and -$16.78 million in losses. Loss per share was -$0.98.
| Revenue | 44.38M |
| Gross Profit | 16.24M |
| Operating Income | -21.61M |
| Pretax Income | -22.80M |
| Net Income | -16.78M |
| EBITDA | -14.83M |
| EBIT | -21.53M |
| Loss Per Share | -$0.98 |
Balance Sheet
The company has $5.28 million in cash and $21.38 million in debt, giving a net cash position of -$16.10 million or -$0.89 per share.
| Cash & Cash Equivalents | 5.28M |
| Total Debt | 21.38M |
| Net Cash | -16.10M |
| Net Cash Per Share | -$0.89 |
| Equity / Book Value | 49.38M |
| Book Value Per Share | 2.74 |
| Working Capital | 26.73M |
Cash Flow
In the last 12 months, operating cash flow was -$11.35 million and capital expenditures -$3.11 million, giving a free cash flow of -$14.46 million.
| Operating Cash Flow | -11.35M |
| Capital Expenditures | -3.11M |
| Free Cash Flow | -14.46M |
| FCF Per Share | -$0.84 |
Margins
Gross margin is 36.59%, with operating and profit margins of -48.70% and -37.81%.
| Gross Margin | 36.59% |
| Operating Margin | -48.70% |
| Pretax Margin | -51.37% |
| Profit Margin | -37.81% |
| EBITDA Margin | -33.41% |
| EBIT Margin | -48.50% |
| FCF Margin | -32.57% |
Dividends & Yields
ProPhase Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | 7.74% |
| Shareholder Yield | 7.74% |
| Earnings Yield | -18.02% |
| FCF Yield | -15.53% |
Analyst Forecast
The average price target for ProPhase Labs is $11.00, which is 113.18% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.00 |
| Price Target Difference | 113.18% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 23, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 23, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ProPhase Labs has an Altman Z-Score of 1.3 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.3 |
| Piotroski F-Score | 1 |